Cargando…
Rationale and Design of the Efficacy and Safety of Esaxerenone in Hypertensive Patients With Left Ventricular Hypertrophy (ESES-LVH) Study ― Protocol for a Multicenter, Open-Label, Exploratory Interventional Study ―
Background: The complication of left ventricular (LV) hypertrophy (LVH) is associated with increased incidence of major cardiovascular events. Hypertension is an independent risk factor among several factors contributing to the development of LVH, and thus appropriate treatment of both hypertension...
Autores principales: | Sueta, Daisuke, Yamamoto, Eiichiro, Usuku, Hiroki, Suzuki, Satoru, Nakamura, Taishi, Matsui, Kunihiko, Akasaka, Takaaki, Shiosakai, Kazuhito, Sugimoto, Kotaro, Tsujita, Kenichi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Japanese Circulation Society
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8811229/ https://www.ncbi.nlm.nih.gov/pubmed/35178486 http://dx.doi.org/10.1253/circrep.CR-21-0122 |
Ejemplares similares
-
Efficacy and Safety of Esaxerenone in Hypertensive Patients with Diabetic Kidney Disease: A Multicenter, Open-Label, Prospective Study
por: Uchida, Haruhito A., et al.
Publicado: (2022) -
Management of hyperkalemia during treatment with mineralocorticoid receptor blockers: findings from esaxerenone
por: Rakugi, Hiromi, et al.
Publicado: (2020) -
Nighttime home blood pressure lowering effect of esaxerenone in patients with uncontrolled nocturnal hypertension: the EARLY-NH study
por: Kario, Kazuomi, et al.
Publicado: (2023) -
The utility of copy number variation (CNV) in studies of hypertension-related left ventricular hypertrophy (LVH): rationale, potential and challenges
por: BoonPeng, Hoh, et al.
Publicado: (2013) -
Efficacy and Safety of Esaxerenone in Hypertensive Patients with Diabetes Mellitus Undergoing Treatment with Sodium-Glucose Cotransporter 2 Inhibitors (EAGLE-DH)
por: Motoki, Hirohiko, et al.
Publicado: (2023)